Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study.
Lancet (London, England), cilt.404, sa.10452, ss.540-553, 2024 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 404 Sayı: 10452
- Basım Tarihi: 2024
- Doi Numarası: 10.1016/s0140-6736(24)01211-x
- Dergi Adı: Lancet (London, England)
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.540-553
- Gazi Üniversitesi Adresli: Evet